2021 annual financial data
Metagenomi Therapeutics 2021 Operating cash flow margin
Direct answer
Operating cash flow margin was 9,982.3%.
Operating income was -23,947,000 USD and net income was -21,442,000 USD.
Operating cash flow was 24,257,000 USD.
Get free Metagenomi Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 243,000 USD
- Operating income
- -23,947,000 USD
- Net income
- -21,442,000 USD
- Operating cash flow
- 24,257,000 USD